报告人： 王蕾 （百济神州生物科技有限公司）
报告时间： 6月19日 15:00-16:00
报告地点： 维格堂319
报告摘要：Compared with the dose exploration of single agent, dose-finding trials for combination therapy are more complex regarding the higher dimensional solution space and unknown drug-drug interactions. The monotonicity of the dose–toxicity and the dose–efficacy relationship usually holds for cytotoxic agents. However, for combination therapies that include at least one novel treatments (e.g., immunotherapy, target therapy), the non-linear relationship may exist between the dose and toxicity/efficacy probability. Thus, the goal of dose-finding trials for combination therapy with novel treatment(s) could be finding the most efficacious dose combination among safe combinations, that is, the biological optimal dose (BOD). In this research, we focus on finding BOD for dual-agent therapies while reducing the number of patients exposed to over-toxic or inefficacious dose combinations
报告人介绍：王蕾于2019年在中国人民大学获得博士学位，毕业后加入百济神州生物科技有限公司做博士后，继而成为高级统计师至今。目前的研究兴趣包括联合治疗的剂量探索试验设计、临界点分析和篮子试验。
邀请人：马学俊